Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
NBIX

Neurocrine

$87.90

-0.49 (-0.55%)

07:34
02/06/19
02/06
07:34
02/06/19
07:34
Recommendations
Neurocrine analyst commentary at Cantor Fitzgerald »

Neurocrine price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBIX

Neurocrine

$87.90

-0.49 (-0.55%)

06:08
02/06/19
02/06
06:08
02/06/19
06:08
Recommendations
Neurocrine analyst commentary at Piper Jaffray »

Neurocrine lack of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBIX

Neurocrine

$87.99

-0.4 (-0.45%)

, ABBV

AbbVie

$79.64

1.1 (1.40%)

16:05
02/05/19
02/05
16:05
02/05/19
16:05
Hot Stocks
Neurocrine expects $20M in revenue milestones under the AbbVie agreement in FY19 »

Neurocrine Biosciences…

NBIX

Neurocrine

$87.99

-0.4 (-0.45%)

ABBV

AbbVie

$79.64

1.1 (1.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 18

    May

NBIX

Neurocrine

$88.09

-0.3 (-0.34%)

16:02
02/05/19
02/05
16:02
02/05/19
16:02
Earnings
Neurocrine reports Q4 EPS 19c, consensus 17c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

NBIX

Neurocrine

$88.20

0.06 (0.07%)

08:31
02/04/19
02/04
08:31
02/04/19
08:31
Recommendations
Neurocrine analyst commentary at Jefferies »

Jefferies sees further…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

VYGR

Voyager Therapeutics

$11.11

3.08 (38.36%)

, NBIX

Neurocrine

$85.13

-3.78 (-4.25%)

07:06
01/30/19
01/30
07:06
01/30/19
07:06
Recommendations
Voyager Therapeutics, Neurocrine analyst commentary at H.C. Wainwright »

Voyager licensing deal…

VYGR

Voyager Therapeutics

$11.11

3.08 (38.36%)

NBIX

Neurocrine

$85.13

-3.78 (-4.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 05

    Feb

NBIX

Neurocrine

$88.91

-1.38 (-1.53%)

, VYGR

Voyager Therapeutics

$8.03

-0.48 (-5.64%)

07:03
01/29/19
01/29
07:03
01/29/19
07:03
Hot Stocks
Neurocrine, Voyager Therapeutics form development, commercialization agreement »

Neurocrine Biosciences,…

NBIX

Neurocrine

$88.91

-1.38 (-1.53%)

VYGR

Voyager Therapeutics

$8.03

-0.48 (-5.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 05

    Feb

NBIX

Neurocrine

$89.22

-2.11 (-2.31%)

07:32
01/24/19
01/24
07:32
01/24/19
07:32
Downgrade
Neurocrine rating change at Needham »

Neurocrine downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

NBIX

Neurocrine

$89.22

-2.11 (-2.31%)

06:53
01/24/19
01/24
06:53
01/24/19
06:53
Downgrade
Neurocrine rating change at Needham »

Neurocrine downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

Over a month ago
NBIX

Neurocrine

$91.33

-0.13 (-0.14%)

08:42
01/23/19
01/23
08:42
01/23/19
08:42
Downgrade
Neurocrine rating change at JPMorgan »

JPMorgan downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.